Clinical trial designs and models for analgesic medications for acute pain in neonates, infants, toddlers, children, and adolescents: ACTTION recommendations
- PMID: 29140927
- PMCID: PMC5949239
- DOI: 10.1097/j.pain.0000000000001104
Clinical trial designs and models for analgesic medications for acute pain in neonates, infants, toddlers, children, and adolescents: ACTTION recommendations
Abstract
Clinical trials to test the safety and efficacy of analgesics across all pediatric age cohorts are needed to avoid inappropriate extrapolation of adult data to children. However, the selection of acute pain models and trial design attributes to maximize assay sensitivity, by pediatric age cohort, remains problematic. Acute pain models used for drug treatment trials in adults are not directly applicable to the pediatric age cohorts-neonates, infants, toddlers, children, and adolescents. Developmental maturation of metabolic enzymes in infants and children must be taken into consideration when designing trials to test analgesic treatments for acute pain. Assessment tools based on the levels of cognitive maturation and behavioral repertoire must be selected as outcome measures. Models and designs of clinical trials of analgesic medications used in the treatment of acute pain in neonates, infants, toddlers, children, and adolescents were reviewed and discussed at an Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION) Pediatric Pain Research Consortium consensus meeting. Based on extensive reviews and continuing discussions, the authors recommend a number of acute pain clinical trial models and design attributes that have the potential to improve the study of analgesic medications in pediatric populations. Recommendations are also provided regarding additional research needed to support the use of other acute pain models across pediatric age cohorts.
Conflict of interest statement
The views expressed in this article are those of the authors, none of whom have financial conflicts of interest related to the specific issues discussed in this article. ACTTION has received research contracts, grants, or other revenue from the FDA, multiple pharmaceutical and device companies, philanthropy, and other sources. At the time of the consensus meeting on which this article is based, 2 of the authors were employed by companies that provided unrestricted grants to the University of Rochester Office of Continuing Professional Education to support the activities of ACTTION, including the consensus meeting; these companies were Collegium Pharmaceutical, Inc. and Purdue Pharma, LP.
Figures
References
-
- Adlard K. Examining the push-pull method of blood sampling from central venous access devices. J Pediatr Oncol Nurs. 2008;25:200–207. - PubMed
-
- Allegaert K, Vanhaesebrouck S, Verbesselt R, van den Anker JN. In vivo glucuronidation activity of drugs in neonates: Extensive interindividual variability despite their young age. Ther Drug Monit. 2009;31:411–415. - PubMed
-
- Anand KJ. Clinical importance of pain and stress in preterm neonates. Biol Neonate. 1998;73:1–9. - PubMed
-
- Anand KJ, Aranda JV, Berde CB, Buckman S, Capparelli EV, Carlo W, Hummel P, Johnston CC, Lantos J, Tutag-Lehr V, Lynn AM, Maxwell LG, Oberlander TF, Raju TN, Soriano SG, Taddio A, Walco GA. Summary proceedings from the Neonatal Pain-Control Group. Pediatrics. 2006;117(Suppl 1):S9–S22. - PubMed
-
- Anand KJ, Hall RW, Desai N, Shephard B, Bergqvist LL, Young TE, Boyle EM, Carbajal R, Bhutani VK, Moore MB, Kronsberg SS, Barton BA, NEOPAIN Trial Investigators Group Effects of morphine analgesia in ventilated preterm neonates: primary outcomes from the NEOPAIN randomised trial. Lancet. 2004;363:1673–1682. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
